Enlivex Says 79.2% Of Patients Aged 64+ Responded To Allocetra vs. 47.6% On Placebo At 12 Months In Phase IIa Knee Osteoarthritis Trial
Share
Why It Matters
Enlivex's new treatment helped more older people with knee pain than fake medicine did. When a medicine works better than placebo in early tests, it shows the idea might be worth developing further.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.